** Shares of biotech firm Patrys fall 50% to A$0.003, a record low
** Stock posts biggest intraday pct fall since Nov. 11, 2008
** Co says cancer therapy antibody PAT-DX1 did not pass some parameters in production
** Adds, it will not use the produced batch for planned Phase-1 clinical trial in cancer patients
** Says it will now pivot towards developing therapeutic possibilities for its other antibody, PAT-DX3
** About 24 mln shares change hands, ~28x the 30-day avg volume
** PNB down ~63% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。